- Invest USD 250 million to advance R&D for neglected tropical diseases (NTDs) and malaria over five years (2021-2025)
- Implement a global access strategy for all new medicines launched
- Increase the number of patients reached with strategic innovative medicines in LMICs1 by at least 200% by 2025 (compared with 2019 baseline)
- Increase the number of patients reached with Novartis global health flagship programs (Malaria, leprosy, Chagas disease, sickle cell disease) in LMICs by at least 50% by 2025 (compared with 2019 baseline)
- Conduct risk assessments for all new eligible suppliers
Climate targets
- 2025: Become carbon neutral from energy in our own operations (scope 1 and 2)2; include environmental criteria in all supplier contracts.
- 2030: Reduce absolute scope 1 and 2 GHG emissions by 90% from a 2022 base year. Reduce absolute scope 3 GHG emissions by 42% within the same timeframe3.
- 2040: Maintain a minimum of 90% absolute scope 1 and 2 emissions from a 2022 base year. Reduce absolute scope 3 GHG emissions 90% from a 2022 base year3.
Learn more about our efforts to reduce our impacts on climate
Water targets
- 2025: Reduce water consumption in our operations by half, with no water quality impacts from manufacturing effluents4
- 2030: Become water neutral in our own operations5, while enhancing water quality wherever we operate6
Waste targets
- 2025: Eliminate polyvinyl chloride (PVC) in packaging7 and reduce the amount of waste sent for disposal by half4
- 2030: Become plastic neutral8, with all new products meeting sustainable design principles
- Maintain gender balanced representation in management
- Review our human resources practices beyond base pay to eliminate any further potential sources of bias from the system by 20279
- Make the requirements of the EU Pay Transparency Directive our global minimum standard for internal pay equity and pay transparency reporting by 20279